Compare SPCE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | IKT |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.3M | 181.9M |
| IPO Year | N/A | 2020 |
| Metric | SPCE | IKT |
|---|---|---|
| Price | $3.77 | $1.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $9.22 | $4.00 |
| AVG Volume (30 Days) | ★ 5.2M | 499.5K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,661,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,656.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $1.33 |
| 52 Week High | $6.77 | $3.49 |
| Indicator | SPCE | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 57.62 |
| Support Level | $2.92 | $1.52 |
| Resistance Level | $4.57 | $1.67 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 49.96 | 65.91 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.